ExThera Medical Corporation is developing revolutionary medical devices that address unmet clinical needs for the treatment of bloodstream infections and pathogen-reduction in blood banking.

Based in Martinez, California with an office in the Netherlands, ExThera Medical Corporation is a privately held medical device company developing innovative, single-use blood filters capable of capturing a broad range of bacteria, viruses, parasites, toxins or other sepsis mediators .

ExThera was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB, at the Karolinska Institute of Stockholm. The company completed a clinical trial of its first product, the Seraph® 100 Microbind® Affinity Blood Filter, in Europe in 2018.

The company is focused is on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, with field deployable versions for biodefense and military use. ExThera also intends to develop diagnostic, oncology, cardiovascular and bioprocessing applications of its technology.

What We’re Addressing

Bloodstream infections are a global health issue and are increasing in incidence despite significant efforts to find effective treatments. If not identified and treated early, these infections can cause serious illness, progress to sepsis and septic shock, and lead to permanent organ damage and death.